Original Article

You have full text access to this OnlineOpen article

Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution

  1. Giuseppe Viale M.D.1,†,*,
  2. Stefano Zurrida M.D.2,
  3. Eugenio Maiorano M.D.3,
  4. Giovanni Mazzarol M.D.1,
  5. Giancarlo Pruneri M.D.1,
  6. Giovanni Paganelli M.D.4,
  7. Patrick Maisonneuve5,
  8. Umberto Veronesi M.D.2

Article first published online: 20 DEC 2004

DOI: 10.1002/cncr.20809

Issue

Cancer

Cancer

Volume 103, Issue 3, pages 492–500, 1 February 2005

Additional Information

How to Cite

Viale, G., Zurrida, S., Maiorano, E., Mazzarol, G., Pruneri, G., Paganelli, G., Maisonneuve, P. and Veronesi, U. (2005), Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer, 103: 492–500. doi: 10.1002/cncr.20809

Author Information

  1. 1

    Department of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan, Milan, Italy

  2. 2

    Department of Senology, European Institute of Oncology and University of Milan, Milan, Italy

  3. 3

    Department of Pathological Anatomy and Genetics, University of Bari, Bari, Italy

  4. 4

    Department of Nuclear Medicine, European Institute of Oncology and University of Milan, Milan, Italy

  5. 5

    Department of Epidemiology and Biostatistics, European Institute of Oncology and University of Milan, Milan, Italy

  1. †

    Fax: (011) 39-02-57489417

*Department of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan, Via Ripamonti, 435, 20141 Milan, Italy

Publication History

  1. Issue published online: 20 JAN 2005
  2. Article first published online: 20 DEC 2004
  3. Manuscript Accepted: 8 OCT 2004
  4. Manuscript Revised: 4 OCT 2004
  5. Manuscript Received: 23 AUG 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (94K)

REFERENCES

  • 1
    Fisher B, Slack N, Katrych D, Wolmark N. Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet. 1975; 140: 528–534.
  • 2
    Nemoto T, Vana J, Bedwani RN, Baker R, McGregor F, Murphy G. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980; 45: 2917–2924.
    Direct Link:
  • 3
    Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with a median follow-up of 18 years. J Clin Oncol. 1989; 7: 1239–1251.
  • 4
    Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet. 1992; 351: 71–85.
  • 5
    Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. An overview of the randomized trials. Lancet. 1998; 351: 1451–1467.
  • 6
    Chua B, Ung O, Taylor R, Boyages J. Frequency and predictors of axillary lymph node metastases in invasive breast cancer. ANZ J Surg. 2001; 71: 723–728.
    Direct Link:
  • 7
    Tabar L, Duffy SW, Vitak B, Chen HH, Prevost TC. The natural history of breast carcinoma. What have we learnt from screening? Cancer. 1999; 86: 449–462.
  • 8
    Schwartz GF, Giuliano AE, Veronesi U, Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer. 2002; 94: 2542–2551.
    Direct Link:
  • 9
    Silverstein MJ, Gierson ED, Waisman JR, Colburn WJ, Gamagami P. Predicting axillary node positivity in patients with invasive carcinoma of the breast by using a combination of T category and palpability. J Am Coll Surg. 1995; 180: 700–704.
  • 10
    Olivotto IA, Jackson JS, Mates D, et al. Prediction of axillary lymph node involvement of women with invasive breast carcinoma: a multivariate analysis. Cancer. 1998; 83: 948–955.
    Direct Link:
  • 11
    Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg. 2001; 25: 767–772.
  • 12
    Barth A, Craig PH, Silverstein MJ. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer. 1997; 79: 1918–1922.
    Direct Link:
  • 13
    Gann PH, Colilla SA, Gapstur SM, Winchester DJ, Winchester DP. Factors associated with axillary lymph node metastasis from breast carcinoma. Cancer. 1999; 86: 1511–1519.
    Direct Link:
  • 14
    Gajdos C, Tartter PI, Bleiweiss IJ. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann Surg. 1999; 220: 692–696.
  • 15
    Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989; 63: 181–187.
    Direct Link:
  • 16
    Chadha M, Chabon AB, Friedmann P, Vikram B. Predictors of axillary lymph node metastases in patients with T1 breast cancer. A multivariate analysis. Cancer. 1994; 73: 350–353.
    Direct Link:
  • 17
    Ahlgren J, Stal O, Westman G, Arnesson LG. Prediction of axillary lymph node metastases in a screened breast carcinoma population. South-East Sweden Breast Cancer Group. Acta Oncol. 1994; 33: 603–608.
  • 18
    Giuliano AE, Barth AM, Spivack B, Beitsch PD, Evans SW. Incidence and predictors of axillary metastasis in T1 carcinoma of the breast. J Am Coll Surg. 1996; 183: 185–189.
  • 19
    Choong PL, deSilva CJ, Dawkins HJ, et al. Predicting axillary lymph node metastases in breast carcinoma patients. Breast Cancer Res Treat. 1996; 37: 135–149.
  • 20
    Fein DA, Fowble BL, Hanlon AL, et al. Identification of women with T1-T2 breast cancer at low risk of positive axillary nodes. J Surg Oncol. 1997; 65: 34–39.
    Direct Link:
  • 21
    Harden SP, Neal AJ, Al-Nasiri N, Ashley S, Querci della Rovere G. Predicting axillary lymph node metastases in patients with T1 infiltrating ductal carcinoma of the breast. Breast. 2001; 10: 155–159.
  • 22
    Ravdin PM, De Laurentiis M, Vendely T, Clark GM. Prediction of axillary lymph node status in breast cancer patients by prognostic indicators. J Natl Cancer Inst. 1994; 86: 1771–1775.
  • 23
    Andea AA, Bouwman D, Wallis T, Visscher DW. Correlation of tumor volume and surface area with lymph node status in patients with multifocal/multicentric breast carcinoma. Cancer. 2004; 100: 20–27.
    Direct Link:
  • 24
    Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst. 1999; 91: 368–373.
  • 25
    Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003; 349: 546–553.
  • 26
    Viale G, Bosari S, Mazzarol GM, et al. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer. 1999; 85: 2433–2438.
    Direct Link:
  • 27
    Viale G, Maiorano E, Mazzarol G, et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer. 2001; 92: 1378–1384.
    Direct Link:
  • 28
    World Health Organization. Histological typing of breast tumors. 2nd ed. Berlin: Springer Verlag, 1981.
  • 29
    Rosen PP, Oberman HA. Tumors of the mammary gland. In: RosenPP, editor. Atlas of tumor pathology. 3rd series. Washington, DC: Armed Forces Institute of Pathology, 1993: 157–257.
  • 30
    Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403–410.
    Direct Link:
  • 31
    Rosen PP, Oberman HA. Tumors of the mammary gland. In: RosenPP, editor. Atlas of tumor pathology. 3rd series. Washington, DC: Armed Forces Institute of Pathology, 1993: 161–163.
  • 32
    Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997; 349: 1864–1867.
  • 33
    Jacobs TW, Gown AM, Yaziji H. Specificity of Herceptest in determining HER2/neu status of breast cancer using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999; 17: 1983–1987.
  • 34
    Sobin LH, Wittekind CH. Classification of malignant tumours. 6th ed. New York: Wiley-Liss, 2002.
View Full Article (HTML) Get PDF (94K)